Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.54 |
| ▸ | PARP1 known ✓ | P09874 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.60 |
| ▸ | CES2 | O00748 | 2/20 | 0.59 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28021646 | 1.00 | MAP4K4 (0.60) | MAP4K4CES2CES1LMNATSHR | |
| Hydrochloric Acid SCHEMBL3772040 | 1.00 | MAP4K4 (0.60) | MAP4K4CES2CES1LMNATSHR | |
| SCHEMBL29959902 | 0.97 | MAP4K4 (0.62) | MAP4K4CES2CES1LMNATSHR | |
| SCHEMBL77931 | 0.97 | MAP4K4 (0.62) | MAP4K4CES2CES1LMNATSHR | |
| Bromide SCHEMBL28799121 | 0.95 | MAP4K4 (0.60) | MAP4K4CES2CES1LMNATSHR | |
| Iodide SCHEMBL19056893 | 0.95 | MAP4K4 (0.60) | MAP4K4CES2CES1LMNATSHR | |
| Nitrogen SCHEMBL27780715 | 0.92 | MAP4K4 (0.58) | MAP4K4CES2CES1LMNATSHR | |
| SCHEMBL2689662 | 0.90 | MAP4K4 (0.72) | MAP4K4CES2CES1LMNATSHR | |
| Benzamide SCHEMBL9812910 | 0.88 | PARP1 (0.73) | MAP4K4CES2CES1TSHRALOX15 | |
| 4-Chloroaniline SCHEMBL11600778 | 0.88 | PARP10 (0.61) | MAP4K4CES2CES1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| CN-104744306-A | P-chloroaniline isocyanate preparation method | HUNAN LIJIE BIOCHEMICAL CO LTD | 2015-07-01 | — | — | CN | claimed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | claimed |
| CN-103910650-A | Preparation method for 4-chlorophenylhydrazine hydrochloride | TIANJIN QIDONG CHEMICAL PLANT | 2014-07-09 | — | — | CN | claimed |
| CN-102993056-A | Preparation method of chlorhexidine compound | GANSU RES INST OF CHEMICAL INDUSTRY | 2013-03-27 | — | — | CN | claimed |
| CN-102993044-A | Preparation method of 4-chlorophenylhydrazine hydrochloride | TIANJIN SHI TIANCHUAN HUAGONG CO LTD | 2013-03-27 | — | — | CN | claimed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | claimed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| CN-101565839-B | Cyanogen to cyanogen-free alkali environment-friendly galvanizing brightener | WUHAN FENGFAN ELECTROPLATING TECHNOLOGY CO LTD | 2011-04-06 | — | — | CN | claimed |
| CN-101555609-B | An environment-protective alkali galvanization composition brightener for transformation from cyanide to non-cyanide | WUHAN FENGFAN ELECTROPLATING TECHNOLOGY CO LTD | 2010-08-04 | — | — | CN | claimed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
| CN-101565839-A | Cyanogen to cyanogen-free alkali environment-friendly galvanizing brightener | WUHAN FENGZHENG ELECTROPLATING (CN) | 2009-10-28 | — | — | CN | claimed |
| CN-101555609-A | An environment-protective composition brightener for transformation between alkali non-cyanide galvanization and alkali cyanide galvanization | WUHAN FENGFAN ELECTROPLATING T (CN) | 2009-10-14 | — | — | CN | claimed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | claimed |
| CN-101081845-A | Substituted sulphone and sulphonamide compounds useful for the treatment of obesity, type II diabetes and cns disorders | BIOVITRUM AB (SE) | 2007-12-05 | — | — | CN | claimed |
| CN-1662521-A | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2005-08-31 | — | — | CN | claimed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | claimed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | claimed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | claimed |
| US-12559461-B2 | Antibiotic adjuvant compounds | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2026-02-24 | — | — | US | disclosed |
| US-20230286922-A1 | ANTIBIOTIC ADJUVANT COMPOUNDS | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-09-14 | — | — | US | disclosed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-115003279-A | Prodrug compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-3187492-A1 | PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY | The University of Tokyo (JP) | 2017-07-05 | — | — | EP | disclosed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| CN-105461724-A | Nitrogen-containing bridged ring compound having insect disinfestation activity, preparation and uses thereof | UNIV EAST CHINA SCIENCE & TECH | 2016-04-06 | — | — | CN | disclosed |
| CN-104744306-A | P-chloroaniline isocyanate preparation method | HUNAN LIJIE BIOCHEMICAL CO LTD | 2015-07-01 | — | — | CN | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8796180-B2 | Aminoquinazoline compounds for combating invertebrate pests | BASF SE (DE) | 2014-08-05 | — | — | US | disclosed |
| CN-103910650-A | Preparation method for 4-chlorophenylhydrazine hydrochloride | TIANJIN QIDONG CHEMICAL PLANT | 2014-07-09 | — | — | CN | disclosed |
| CN-103848752-A | Novel synthesis process of P-chlorophenylhydrazine hydrochloride | UNIV NANJING SCIENCE & TECH | 2014-06-11 | — | — | CN | disclosed |
| CN-102993056-A | Preparation method of chlorhexidine compound | GANSU RES INST OF CHEMICAL INDUSTRY | 2013-03-27 | — | — | CN | disclosed |
| CN-102993044-A | Preparation method of 4-chlorophenylhydrazine hydrochloride | TIANJIN SHI TIANCHUAN HUAGONG CO LTD | 2013-03-27 | — | — | CN | disclosed |
| CN-101928246-B | N-[(1-aryl-3-substituted phenyl-pyrazol-4-yl) methenyl]-2-hydroxyl benzoyl hydrazine compound or pharmaceutically acceptable salts and preparation method thereof | UNIV TIANJIN TECHNOLOGY | 2013-02-27 | — | — | CN | disclosed |
| EP-2480537-A1 | AMINOQUINAZOLINE COMPOUNDS FOR COMBATING INVERTEBRATE PESTS | BASF SE (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-20120178622-A1 | Aminoquinazoline Compounds for Combating Invertebrate Pests | BASF SE (DE) | 2012-07-12 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| CN-101565839-B | Cyanogen to cyanogen-free alkali environment-friendly galvanizing brightener | WUHAN FENGFAN ELECTROPLATING TECHNOLOGY CO LTD | 2011-04-06 | — | — | CN | disclosed |
| WO-2011036074-A1 | AMINOQUINAZOLINE COMPOUNDS FOR COMBATING INVERTEBRATE PESTS | BASF SE (DE) | 2011-03-31 | — | — | WO | disclosed |
| CN-101928246-A | N-[(1-aryl-3-substituted phenyl-pyrazol-4-yl) methenyl]-2-hydroxyl benzoyl hydrazine compound or pharmaceutically acceptable salts and preparation method thereof | UNIV TIANJIN TECHNOLOGY | 2010-12-29 | — | — | CN | disclosed |
| CN-101555609-B | An environment-protective alkali galvanization composition brightener for transformation from cyanide to non-cyanide | WUHAN FENGFAN ELECTROPLATING TECHNOLOGY CO LTD | 2010-08-04 | — | — | CN | disclosed |
| CN-101624371-A | 4-carbostyril and 4H-1,4-benzothiazine derivatives and preparation method and application thereof | UNIV CHINA PHARMA | 2010-01-13 | — | — | CN | disclosed |
| CN-101565839-A | Cyanogen to cyanogen-free alkali environment-friendly galvanizing brightener | WUHAN FENGZHENG ELECTROPLATING (CN) | 2009-10-28 | — | — | CN | disclosed |
| CN-101555609-A | An environment-protective composition brightener for transformation between alkali non-cyanide galvanization and alkali cyanide galvanization | WUHAN FENGFAN ELECTROPLATING T (CN) | 2009-10-14 | — | — | CN | disclosed |
| EP-1897881-A2 | Compounds useful for the treatment of obesity, type II diabetes and CNS disorders | Biovitrum AB (publ) (SE) | 2008-03-12 | — | — | EP | disclosed |
| CN-101081845-A | Substituted sulphone and sulphonamide compounds useful for the treatment of obesity, type II diabetes and cns disorders | BIOVITRUM AB (SE) | 2007-12-05 | — | — | CN | disclosed |
| CN-1907982-A | New compounds useful for the treatment of obesity,type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2007-02-07 | — | — | CN | disclosed |
| CN-1662521-A | Novel compounds useful for the treatment of obesity, type II diabetes and CNS disorders | BIOVITRUM AB (SE) | 2005-08-31 | — | — | CN | disclosed |
| EP-1513828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | Biovitrum AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| CN-1038248-C | Diguanide derivatives, process of preparation thereof and disinfetants containing them | OTSUKA CHEMCIAL CO LTD (JP) | 1998-05-06 | — | — | CN | disclosed |
| CN-1065453-A | Biguanide derivative, its manufacture method and the Herb of Common violet that contains this derivative | OTSUKA CHEMICAL CO LTD (JP) | 1992-10-21 | — | — | CN | disclosed |
| CN-1065453-A | Biguanide derivative, its manufacture method and the Herb of Common violet that contains this derivative | OTSUKA CHEMICAL CO LTD (JP) | 1992-10-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286922-A1 | ANTIBIOTIC ADJUVANT COMPOUNDS | MYD88, TLR5, TLR8 | CA2 4387/4885PARP1 3913/4885MAP4K4 2094/4885 |
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | CA2 1228/4885PARP1 4152/4885MAP4K4 3061/4885 |
| US-20120022060-A1 | Tricyclic Azaindoles | AZI2, DCK, PPP2CA | CA2 4497/4885PARP1 845/4885MAP4K4 203/4885 |
| US-12559461-B2 | Antibiotic adjuvant compounds | MYD88, TLR5, TLR4 | CA2 4031/4885PARP1 4393/4885MAP4K4 2938/4885 |
| US-20120178622-A1 | Aminoquinazoline Compounds for Combating Invertebrate Pests | AAAS, ATL3, H1-3 | CA2 3458/4885PARP1 1559/4885MAP4K4 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.